STRATEC SE

Earnings Release • Nov 20, 2002

News Details

Corporate | 20 November 2002 17:00

Stratec Biomedical Sys. english

STRATEC Biomedical Systems AG is on track Corporate-news announcement sent by DGAP. The sender is solely responsible for the contents of this announcement. ——————————————————————————– STRATEC Biomedical Systems AG is on track Publication of the 3rd. quarter figures Birkenfeld, Nov. 20, 2002 STRATEC Biomedical Systems AG (WKN 728 900) could rise the earnings before tax (EBT) according to IAS, by 82.3% to EUR 1.074m (previous year EUR 0.589m). This improvement in earnings is primarily attributable to measures announced to reduce the material quota (the ratio of materials usage to sales), which was decreased from 67.2% to 60.6%. As at Sept. 30, 2002 we achieved a surplus for the period amounting to EUR 0.667m, according to IAS, as against EUR 0.365m in the previous year. This corresponds to earnings per share of EUR 0.20 (previous year: EUR 0.12, pursuant to IAS 33 as at Sept. 30, 2002), and this although the underlying number of shares has been increased by 10% due to a capital increase in spring-time 2002. The cash flow, according to IAS (flow of funds from current activities, cumulative as at Sept.30, 2002), had a clearly positive development at EUR 0.754m (previous year EUR -0.097m). Although the demand from one particular OEM partner was rather muted, STRATEC AG was able to increase the turnover as at Sept. 30, 2002 (according to IAS) as forecast, to EUR 19.293m. The turnover therefore exceeded the equivalent figure for the previous year (EUR 18.989m) by 1.6%. STRATEC Biomedical Systems AG is currently working on several major projects which will reach the phase of clinical testing and market launch in the periods to come. The Board of Management of STRATEC Biomedical Systems AG is confident to achieve the targeted objectives for the fiscal year 2002. For further information please contact: STRATEC Biomedical Systems AG Investor Relations Andre Loy Gewerbestraße 37 75217 Birkenfeld Tel. +49 (0) 70 82 79 16 43 Fax. +49 (0) 70 82 2 05 59 eMail: ir@stratec-biomedical.de Internet: www.stratec-biomedical.de end of message, (c)DGAP 20.11.2002 ——————————————————————————– WKN: 728900; ISIN: DE0007289001; Index: SDAX Listed: Geregelter Markt in Stuttgart und Frankfurt (SMAX); Freiverkehr in Berlin, Düsseldorf und Hamburg 201700 Nov 02